BMY vs PFE

For growth investors, Bristol-Myers Squibb Company (BMY) is the stronger pick with -0.

2% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Bristol-Myers Squibb Company (BMY) a "Hold" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

5x versus Pfizer Inc. at 19. 4x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Bristol-Myers Squibb Company (BMY) delivered a total return of +5.

9%, compared to -13. 2% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: PFE returned +30. 5% versus BMY's +8. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

50β versus Pfizer Inc. 's 0. 54β — meaning PFE is approximately 8% more volatile than BMY relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bristol-Myers Squibb Company (BMY) is pulling ahead at -0.

2% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, BMY leads at 1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus 24. 7% for PFE. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 9. 0x for Bristol-Myers Squibb Company — 0. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMY: 8. 9% to $62. 00.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 4. 3% for Bristol-Myers Squibb Company (BMY).

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 3% yield). Both have compounded well over 10 years (BMY: +8. 0%, PFE: +30. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BMY is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.